Here we describe new families of multi-target directed ligands obtained by linking antioxidant cinnamic-related structures with N-benzylpiperidine (NBP) or N,Ndibenzyl(N-methyl)amine (DBMA) fragments. Resulting hybrids, in addition to their antioxidant and neuroprotective properties against mitochondrial oxidative stress, are active at relevant molecular targets in Alzheimer's disease, such as cholinesterases (hAChE and hBuChE) and monoamine oxidases (hMAO-A and hMAO-B). Hybrids derived from umbellic -NBP (8), caffeic -NBP (9), and ferulic -DBMA (12) displayed balanced biological profiles, with IC 50 s in the low-micromolar and submicromolar range for hChEs and hMAOs, and an antioxidant potency comparable to vitamin E. Moreover, the caffeic -NBP hybrid 9 is able to improve the differentiation of adult SGZ-derived neural stem cells into a neuronal phenotype in vitro.
Introduction
The current therapeutic arsenal against Alzheimer's disease (AD) is composed by three acetylcholinesterase (AChE) inhibitors (donepezil, rivastigmine, and galantamine) and one antagonist of the N-methyl-D-aspartate (NMDA) receptor, named memantine [1] . These marketed drugs modestly alleviate some symptoms, like memory impairment, but they do not stop neuronal degeneration or repair brain damage [2] .
Nowadays it is widely accepted that neuronal loss in AD and other neurodegenerative diseases is the outcome of a wide variety of factors highly interconnected. In the core of such complex scenario, oxidative stress emerges as an important actor that could trigger many pathological cascades [3] . The oxidative stress hypothesis states that toxicity exerted by free radical species is in the basis of many abnormal signalling pathways that finally lead to neuronal death. Reactive entities are able to interact with lipids in cellular membranes, altering their composition, function and permeability. By-products from peroxidation of unsaturated fatty acids include highly reactive and toxic species such as 4-hydroxynonenal, malondialdehyde and acrolein, which seems to be especially increased in AD. Moreover, other vital biomolecules are affected by free radicals. Arachidonic acid and docosahexaenoic acid, two important molecules whose concentrations reach the highest levels in brain, are susceptible to be oxidized under oxidative conditions [4] [5] [6] .
Despite of the effective system of the human body to counteract the harmful effects of oxidative metabolism (e.g., superoxide dismutase, aldehyde dehydrogenase, and glutathione peroxidase), during aging the brain becomes particularly sensitive to oxidative damage due to its great requirement of oxygen, its high levels of unsaturated fatty acids and its relatively low levels of antioxidant enzymes [7] . 6 demonstrated that several antioxidants promote the transition of pluripotent stem-cells to a fully reprogrammed phenotype and increase the number of connections between neurons [18, 19] According to the oxidative stress hypothesis, antioxidants could play an important role in prevention and therapy of AD. Among the most investigated natural antioxidants, there are some derivatives of the cinnamic acid (e.g., ferulic, caffeic, pcoumaric and umbellic acids) and natural molecules containing its structure, such as curcumin derivatives [20] [21] [22] [23] [24] [25] (Figure 1 ).
Figure 1.
Structures of natural antioxidants containing the cinnamic acid structure (pcoumaric, caffeic, umbellic, and ferulic acids, curcumin), donepezil, AP2238, and new cinnamic -N-benzylpiperidine (NBP) (1) (2) (3) (4) (5) (6) (7) (8) (9) and cinnamic -N,N-dibenzyl(Nmethyl)amine (DBMA) hybrids (10) (11) (12) (13) (14) (15) (16) (17) . 7 However, antioxidant molecules per se might not be sufficient to treat such highly complex pathologies like AD, as shown by the ambiguous results obtained from several clinical trials with this kind of compounds [26] . In this sense, multi-target directed ligands (MTLs) that combine antioxidant properties and other activities in additional targets of interest for AD (e.g, AChE, BACE, MAO) may greatly improve the treatment of the disease. In the last years, several MTLs have been developed [27, 28] , such as ladostigil [(R)-3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-yl ethyl(methyl)carbamate] [29] . This dual AChE-MAO inhibitor enhances the expression of neurotrophic factors and reverses neuronal damage by promoting endogenous neurogenic processes.
Continuing with our interest in AD-directed drugs, which some of them displayed interesting neurogenic properties [30] [31] [32] [33] [34] [35] , in this work we planned to obtain new cinnamic-based antioxidants endowed with other fragments with AChE and MAO inhibition. For this purpose, we selected N-benzylpiperidine (NBP) and N,Ndibenzyl(N-methyl)amine (DBMA) fragments, which are present in the well-known AChE inhibitors donepezil and 3-(4-((benzyl(methyl)amino)methyl)phenyl)-6,7-dimethoxy-2H-chromen-2-one (AP2238), respectively [36] [37] [38] (Figure 1 ).
In this work, we describe the synthesis of new cinnamic -N-benzylpiperidine (1) (2) (3) (4) (5) (6) (7) (8) (9) and cinnamic -N,N-dibenzyl(N-methyl)amine (10) (11) (12) (13) (14) (15) (16) (17) hybrids and their biological evaluation, which includes inhibition of human cholinesterases (hChEs) and monoamino oxidases (MAOs), a study of their oxygen radical absorbance capacity (ORAC) and their neuroprotective effects against death provoked by mitochondrial oxidative stress in the human neuroblastoma cell line SH-SY5Y. Finally, we explored the neurogenic effects of a selected hybrid using primary SGZ stem-cells from adult mice. 8 
Results and discussion
Synthesis of hybrids 1-17. Scheme 1 illustrates the synthetic routes to obtain cinnamic-NBP (1-9) and cinnamic-DBMA hybrids (10-17) from commercially available cinnamic-derived acids and amines carrying the NBP or the DBMA fragments. 2-(1-Benzylpiperidin-4-yl)ethan-1-amine is commercially available, whereas 3-and 4-((benzyl(methyl)amino)methyl)aniline were obtained as previously described (see Supplementary Information for further details). In a microwave oven operating at 120 ºC, activation of the corresponding acid was performed with 1,1'-carbonyldiimidazole (CDI) in THF during 7 minutes and the subsequent reaction with the proper amine during 10 or 40 minutes depending on its character, aliphatic or aromatic. Derivatives 1-5 and 10-15 were isolated in yields comprised between 60 and 95% (Scheme 1).
Deprotection of methoxy groups was carried out under mild conditions by overnight treatment with boron tribromide (BBr 3 ) at room temperature, giving hybrids 6-9,16,17 in moderate to excellent yields (60-97%). It is worth mentioning that increased yields were obtained when we used 1 equiv of BBr 3 per ether group to be cleavage, plus an additional equiv per each heteroatom included in the molecule, due to the well-known complexation tendency of boron with free electron pairs, which decreases the effective amount of reactive BBr 3 [39, 40] .
All cinnamic-based hybrids (1-17) were purified using an automatic chromatographic apparatus (IsoleraOne, Biotage) in silica gel cartridges and were characterized by their analytical (HPLC, HRMS) and spectroscopic data ( 1 H NMR, Biological Evaluation. The preliminary biological evaluation of new cinnamic-based hybrids comprised: (i) Inhibition of recombinant human cholinesterases (hAChE and hBuChE), using donepezil as reference and following the spectrophotometric method described by Ellman et al. [41] .
(ii) Inhibition of recombinant human monoamine oxidases (hMAO-A and hMAO-B), expressed in baculovirus infected BTI insect cells, using three known MAO inhibitors as references (selegiline, iproniazid, and moclobemide) and following a described method [42] . (iii) Assessment of the radical scavenger ability, using trolox (an analogue of vitamin E) as internal standard and 10 following the oxygen radical absorbance capacity method (ORAC), as previously described [43, 44] . Results are gathered in Table 1 .
Regarding hAChE and hBuChE, the NBP series displayed a moderate inhibition of both isoforms, with IC 50 in the micro-and sub-micromolar range, and in general, with a slight preference for hAChE. Methoxy derivatives showed just a little better inhibition than their hydroxy counterparts. The best hChEs inhibitor of the NBP series is 5 that unexpectedly exhibited the inversed preference than the rest of its congeners, with an IC 50 = 76 nM towards hBuChE. Replacement of the NBP part with a DBMA fragment maintained the hAChE inhibition in the low-micromolar range, but reduced drastically the potency towards hBuChE. Thus, the cinnamic -DBMA hybrids showed a better hAChE-selectivity than the cinnamic -NBP series.
In relation to hMAO-A and hMAO-B inhibition, both series displayed almost the same pattern. Methoxy derivatives were found to be inactive and only hybrids bearing a p-hydroxy group in the cinnamic fragment showed a meaningful inhibitory activity in the micromolar range, with a slight preference for the hMAO-A isoform. In contrast, when the hydroxy group was located at position meta-the resulting derivative was almost inactive, as it can see in the couple 17 (7-OH, active) and 16 (6-OH, not active).
Maintaining the p-hydroxy group, introduction of a second hydroxy functionality in position ortho-or meta-increased the inhibitory potency towards both isoforms. In fact,
8 (5,7-diOH) and 9 (6,7-diOH) were the most potent inhibitors of hMAO-A and hMAO-B described in this work, displaying one-digit-micromolar IC 50 s values for both enzymes. These inhibitory activities are comparable with iproniazide, a drug that has been clinically used for treating depression in humans [45] and that was employed in our MAO experiments for comparative purposes ( showed a potent antioxidant capacity of 1.8 trolox equivalents, nanomolar and submicromolar inhibition of hBuChE and hAChE (76 nM and 0.39 µM, respectively), and moderate non-selective inhibitory activity towards hMAO-A and hMAO-B in the micromolar range (11 μM and 13 μM, respectively). Interestingly, dihydroxy substituted hybrids derived from umbellic acid 8 (5,7-diOH) and caffeic acid 9 (6,7-diOH) exhibited more balanced profiles, with IC 50 s in the one-digit-micromolar and submicromolar range for enzymatic targets (hChEs and hMAOs) and an antioxidant potency comparable to vitamin E. Similar balanced multifunctional profile was found in the ferulic -DBMA hybrid 12, which showed one-digit-micromolar IC 50 's in all tested targets (hAChE: 6.0 μM; hBuChE: 5.9 μM; hMAO-A: 4.5 μM; hMAO-B: 7.7 μM) and a radical scavenger activity 1.5-fold more potent than vitamin E.
Moreover, cinnamic -DBP and cinnamic -DBMA hybrids were tested as inhibitors of the human recombinant beta-secretase (hBACE-1), using a fluorescence resonance energy transfer (FRET)-based assay as previously described [40, 46] .
Cinnamic -DBMA hybrids 12-15 were capable to inhibit poorly this enzyme with percentages around 23-33% at 10 μM (data not shown).
To evaluate the behaviour of new hybrids at the cellular level, their neuroprotective capacity against mitochondrial oxidative stress were tested, using the human neuroblastoma cell line SH-SY5Y and a toxic insult composed by the mixture of rotenone and oligomycin A at concentrations of 30 and 10 μM, respectively. The combination of such toxics blocks complexes I and V of the mitochondrial electronic chain, generating a great amount of free radicals that finally provoke mitochondrial dysfunction and cell death [47, 48] . Therefore, this assay is considered a good model of 14 mitochondrial oxidative stress. Compounds were co-incubated at four concentrations (0.1, 0.3, 1, and 3 μM) with a mixture of rotenone and oligomycin A, and maintained for 24 h period in cell culture. Afterwards, the percentage of cell viability was measured as MTT reduction [49] . The best antioxidant hybrid 16 (ORAC = 3.2 trolox equiv), the most potent hChE inhibitor 5 (IC 50 = 76 nM) and ferulic-DBMA hybrid 12 with a wellbalanced target profile in the micromolar range (hAChE: 6.0 μM; hBuChE: 5.9 μM; hMAO-A: 4.5 μM; hMAO-B: 7.7 μM) were chosen for this neuroprotective assay.
Melatonin was used as a positive reference [32] , and results are shown in Figure 2 .
Tested compounds protected around 30-35% of cells at a concentration of 0.3 μM, although a dose-dependent relationship was not observed in these experiments.
Nevertheless, in any case they did not potentiate the toxicity exerted by rotenone/oligomycin A, which could be assumed as a lack of toxicity of our newly obtained hybrids. Thus, it is expected that these new cinnamic-based hybrids could increase patient memory, decrease free radical levels, protect neurons from mitochondrial oxidative stress, and promote brain auto-repair processes. This biological profile highlights these new cinnamic-based hybrids as useful multi-target prototypes in the search for new
Experimental

Chemistry. General Methods
Reagents and solvents were purchased from common commercial suppliers, mostly
Sigma-Aldrich, and were used without further purification. Analytical thin-layer chromatography (TLC) was carried out using Merck silica gel 60 F254 plates, and the The corresponding acid (1 mmol) and CDI (1.15 mmol) were mixed into a microwave tube under nitrogen atmosphere. The tube was sealed up and 3 mL of anhydrous THF were added using a syringe to dissolve the mixture (CO 2 ↑). This solution was heated into a microwave reactor at 120 ⁰C during 7 min to complete the acid activation. Afterward, a solution of 1.2 mmol of the corresponding amine in 2 mL of THF was added with a syringe into the tube; this mixture was heated at 120 ⁰C during 10 minutes for NBP derivatives and 40 min for DBMA hybrids. After solvent evaporation under reduced pressure, the crude was re-dissolved in 25 mL of EtOAc and washed with water (3x5 mL) and brine (3x5 mL), dried over magnesium sulfate and concentrated under reduced pressure. The crude was purified by column chromatography using EtOAc:MeOH (9:1) or hexane/EtOAc (0→70%) as eluent.
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(3,4-dimethoxyphenyl)acrylamide (1)
From 3,4-dimethoxy cinnamic acid (0.100 g, 0.48 mmol) and 2-(1-benzylpiperidin- 
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(3-methoxyphenyl)acrylamide (2)
From 3-methoxy cinnamic acid (0. HPLC purity 100%.
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(4-methoxyphenyl)acrylamide (3)
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(2,4-dimethoxyphenyl)acrylamide (4)
From 2,4-dimethoxy cinnamic acid (0.300 g, 1.44 mmol) and 2-(1-benzylpiperidin- 
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (5)
From ferulic acid (0.100 g, 0.50 mmol) and 2-(1-benzylpiperidin-4-yl)ethan-1- HPLC purity 97%.
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(2,4-dimethoxyphenyl)acrylamide (10)
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(3,4-dimethoxyphenyl)acrylamide (11)
(E)-N-(3-((Benzyl(methyl)amino)methyl)phenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (12)
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylamide (13)
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(3-methoxyphenyl)acrylamide (14)
(E)-3-(3-Methoxyphenyl)acrylic acid (0.150 g, 1.00 mmol) and 4-((benzyl(methyl)amino)methyl)aniline (0.220 g, 1.00 mmol), were reacted as described in the general procedure b to obtain 14 (0.255 g, 79%) as a white amorphous solid of HPLC purity 99%.
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(4-methoxyphenyl)acrylamide (15)
4
General procedure for deprotection of methoxy substituted hybrids.
To the corresponding methoxy derivative (0.1 mmol) dissolved in 3 mL of anhydrous THF, was added slowly under magnetic stirring, 1 equivalent of BBr 3 per each heteroatom present in the molecule; air was displaced by N 2 and the mixture was allowed to react overnight at room temperature. Reaction was quenched with methanol (MeOH) (dropwise until end of effervescence) and the solvent evaporated under reduced pressure to eliminate the remaining BBr 3 , this process was repeated several times depending on the quantity of BBr 3 used, until no fumes were observed when adding MeOH. When necessary, purification was carried out by column chromatography using a gradient of EtOAc/MeOH 0→10% as eluent 29 
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(3-hydroxyphenyl)acrylamide (6)
From 2 (0.1 g, 0.26 mmol) and BBr 3 (7 mmol 
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(4-hydroxyphenyl)acrylamide (7)
From 3 (0.1 g, 0.26 mmol) and BBr 3 (7 mmol 
(E)-N-(2-(1-Benzylpiperidin-4-yl)ethyl)-3-(3,4-dihydroxyphenyl)acrylamide (9)
From 5 (0.1 g, 0.25 mmol) and BBr 3 (7 mmol) the caffeic -NBP hybrid 9 was obtained (60 mg, 65%) as a white amorphous solid of mp: 164-166 ºC. 
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(3-hydroxyphenyl)acrylamide (16)
(E)-N-(4-((Benzyl(methyl)amino)methyl)phenyl)-3-(4-hydroxyphenyl)acrylamide (17)
From 
Biochemical Studies
Inhibition of Human AChE and BuChE
Using human recombinant acetylcholinesterase (h-AChE) and butyrylcholinesterase from human serum (h-BuChE), the Ellman method [41] was followed according to the experimental details previously described [50] .
Inhibition of human monoamino oxidases (hMAO-A and hMAO-B).
MAO inhibition measurements were evaluated following the general procedure previously described by us [42] . Briefly, test drugs and adequate amounts of was calculated after subtraction of the background activity, which was determined from wells containing all components except the hMAO isoforms, which were replaced by a sodium phosphate buffer solution.
Oxygen Radical Absorbance Capacity Assay
The ORAC method was followed, using a Polarstar Galaxy plate reader (BMG Labtechnologies GmbH, Offenburg, Germany) with 485-P excitation and 520-P emission filters [43] .
Human BACE1 Inhibition Assay.
This experiment was carried out using fluorescence resonance energy transfer (FRET), according to the protocol described by the manufacturer (Invitrogen) [51] .
Effect of compounds 5, 12 and 16 on R/O-induced oxidative cell injury in SH-
SY5Y cells
Human dopaminergic neuroblastoma SH-SY5Y cells were maintained in a 1:1 mixture of nutrient mixture F-12 and Eagle´s minimum essential medium (EMEM) supplemented with 15 nonessential amino acids, sodium pyruvate (1 mM), 10% heatinactivated FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cultures were seeded into flasks containing supplemented medium and maintained at 37 ºC in a 
Measurement of cell viability
MTT reduction was performed as described [52] . Briefly, 50 µL of the MTT labeling reagent, at a final concentration of 0.5 mg/ml, was added. After incubation for 2 h, in a humidified incubator at 37 ºC with 5% CO 2 and 95% air (v/v), the supernatant was removed, the obtained purple formazan product was re-suspended in 100 μL of Dimethyl Sulfoxide (DMSO). Colorimetric determination of MTT reduction was measured in an ELISA microplate reader at 540 nm. Control cells treated with EMEM were taken as 100% viability.
Neurogenic Assays
Adult (3 months old) male C57BL/6 mice were used following the animal experimental procedures previously approved by the Ethics Committee for Animal
Experimentation of the CSIC in accordance with the European Communities Council, directive 2010/63/EEC and National regulations, normative 53/2013. Special care was taken to minimize animal suffering. Neural stem cells were isolated from the SGZ of the dentate gyrus of the hippocampus of adult mice and cultured as NS according to previously published protocols [53, 54] . Neural stem cells grown as NS were treated for 35 7 days in culture with compound 9 (10 µM). Now, NS were adhered onto 100 μg/mL poly-L-lysine-coated coverslips and treated for 3 additional days in the presence of serum but in the absence of exogenous growth factors to induce differentiation [55] . 
